This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1988:36 Suppl 1:120-2.

doi: 10.2165/00003495-198800361-00023.

Effects of ketanserin on systemic and regional haemodynamics in patients with essential hypertension

Y Ito¹, M Isaka, H Noda, Y Sato, T Fujita

Affiliations

PMID: 3240725
DOI: 10.2165/00003495-198800361-00023

Effects of ketanserin on systemic and regional haemodynamics in patients with essential hypertension

Y Ito et al. Drugs. 1988.

. 1988:36 Suppl 1:120-2.

doi: 10.2165/00003495-198800361-00023.

Authors

Y Ito¹, M Isaka, H Noda, Y Sato, T Fujita

Affiliation

¹ Department of Internal Medicine, University of Tsukuba, Ibaraki, Japan.

PMID: 3240725
DOI: 10.2165/00003495-198800361-00023

No abstract available

PubMed Disclaimer

Similar articles

Haemodynamic changes associated with long term antihypertensive therapy with ketanserin.
Noda H, Isaka M, Ito Y, Fujita T. Noda H, et al. Drugs. 1988;36 Suppl 1:115-9. doi: 10.2165/00003495-198800361-00022. Drugs. 1988. PMID: 3240724 No abstract available.
[What does the introduction of ketanserin for the treatment of arterial hypertension represent?].
Rorive G, Carlier PG, Krzesinski JM. Rorive G, et al. Rev Med Liege. 1988 Mar;43 Suppl 1:50-4. Rev Med Liege. 1988. PMID: 3375650 French. No abstract available.
[The effect of acute administration of ketanserin on the peripheral metabolism of serotonin and hemodynamic indicators in hypertensive patients].
Sebeková K, Raucinová M, Jurecková K. Sebeková K, et al. Bratisl Lek Listy. 1990 Nov;91(11):829-32. Bratisl Lek Listy. 1990. PMID: 2265368 Clinical Trial. Slovak.
The rationale for ketanserin therapy in hypertension.
Hansson L, Hedner T. Hansson L, et al. J Cardiovasc Pharmacol. 1987;10 Suppl 3:S39-44. J Cardiovasc Pharmacol. 1987. PMID: 2446068 Review.
Hemodynamic effects of the anti-hypertensive agent ketanserin in hypertension in man.
Weiss YA, Fournier V, Pannier B, Laurent S, Safar ME. Weiss YA, et al. Acta Cardiol. 1987;42(5):329-37. Acta Cardiol. 1987. PMID: 3321806 Review.

See all similar articles

Cited by

Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.
Brogden RN, Sorkin EM. Brogden RN, et al. Drugs. 1990 Dec;40(6):903-49. doi: 10.2165/00003495-199040060-00010. Drugs. 1990. PMID: 2079001 Review.

References

1. J Cardiovasc Pharmacol. 1987;10 Suppl 3:S45-7 - PubMed
1. J Clin Invest. 1987 Sep;80(3):832-40 - PubMed
1. Fed Proc. 1983 Feb;42(2):182-5 - PubMed
1. Fed Proc. 1983 Feb;42(2):233-7 - PubMed
1. Hypertension. 1986 Feb;8(2):167-73 - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer
Medical
- MedlinePlus Health Information